POLYPEPTIDE ‐ CERULETIDE vs placebo
Leaving the study early · female and male 55‐59 year old (mean) patients with various psychiatric conditions and antipsychotic‐induced tardive dyskinesia
It is very uncertain whether POLYPEPTIDE ‐ CERULETIDE changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
1 finding from 1 review
- Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes onlyRR 1.09 [0.49, 2.4]1 study · 85 participantsVery low